Mechanisms of abnormal platelet aggregation in systemic lupus erythematosus.
Platelet aggregation was measured in 14 patients with systemic lupus erythematosus (SLE) and 13 normal controls. Ten SLE patients (group I) showed decreased responsiveness to collagen, while aggregation was normal in 4 (group II). Group I patients also responded poorly to epinephrine. Platelets from SLE patients did not differ from controls in the production of malondialdehyde in response to N-ethylmaleimide, suggesting intact prostaglandin synthetic pathways. However, a significant decrease (P less than 0.005) in platelet levels of the dense granule constituent, serotonin, was noted in group I SLE patients. Treatment of SLE platelet-rich plasma with deoxyribonuclease (DNase) resulted in enhancement of collagen-induced aggregation in 4 group I SLE patients, but not in 1 group II or 8 normal individuals. These results suggest that defective aggregation in SLE platelets may be partially related to a storage pool deficiency state. However, the ability to restore aggregation to collagen by digestion of platelet-rich plasma with DNase indicates that the defect is reversible and that it is perhaps mediated by plasma or platelet-associated DNA.
D001791:Blood Platelet Disorders / Q000209:etiology*; D001792:Blood Platelets / Q000378:metabolism; D003094:Collagen / Q000494:pharmacology; D004247:DNA / Q000494:pharmacology; D003851:Deoxyribonucleases / Q000494:pharmacology; D004837:Epinephrine / Q000494:pharmacology; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000097:blood* / Q000150:complications; D008315:Malondialdehyde / Q000096:biosynthesis; D010974:Platelet Aggregation / Q000187:drug effects*; D012701:Serotonin / Q000096:biosynthesis
D012701:Serotonin; D008315:Malondialdehyde; D003094:Collagen; D004247:DNA; D003851:Deoxyribonucleases; D004837:Epinephrine